Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00995995

Enrollment

7641

Registered

2009-10-16

Start date

2008-10-31

Completion date

2009-02-28

Last updated

2017-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

Carry out the cost-effectiveness analysis of rosiglitazone on a population in line with the rosiglitazone license and using UK costs

Interventions

DRUGRosiglitazone

Rosiglitazone

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Rosiglitazone Type II Diabetes studies

Exclusion criteria

* Studies without the required outcome

Design outcomes

Primary

Measure	Time frame
Cost-effectiveness of rosiglitazone	From literature

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026